Evaluation of ischemic and bleeding risks associated with 2 parenteral antiplatelet strategies comparing cangrelor with glycoprotein IIb/IIIa inhibitors: An exploratory analysis from the CHAMPION trials

JAMA Cardiology

Volumn 2, Issue 2, 2017, Pages 127-135

  Vaduganathan, Muthiah ^a   Harrington, Robert A ^b   Stone, Gregg W ^c   Deliargyris, Efthymios N ^d   Steg, Ph Gabriel ^e,f,g   Gibson, C Michael ^h   Hamm, Christian W ⁱ   Price, Matthew J ^j   Menozzi, Alberto ^k   Prats, Jayne ^d   Elkin, Steven ^d   Mahaffey, Kenneth W ^b   White, Harvey D ^l   Bhatt, Deepak L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d MEDICINES COMPANY   (United States)

^e INSERM   (France)

^f BICHAT HOSPITAL   (France)

^g ROYAL BROMPTON HOSPITAL   (United Kingdom)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ Kerckhoff Heart and Thorax Center   (Germany)

^j SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^k UNIVERSITY HOSPITAL OF PARMA   (Italy)

^l Green Lane Cardiovascular Service ^*  (New Zealand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BIVALIRUDIN; CANGRELOR; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN IIIA ANTAGONIST; UNCLASSIFIED DRUG; ADENOSINE PHOSPHATE; FIBRINOGEN RECEPTOR; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE CATHETERIZATION AND URGENT INTERVENTION TRIAGE SCALE; ACUTE CORONARY SYNDROME; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASSESSMENT OF HUMANS; BLEEDING; BLEEDING RISK; BLOOD TRANSFUSION; CAUSE OF DEATH; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOBAL USE OF STRATEGIES TO OPEN OCCLUDED CORONARY ARTERIES SCALE; HUMAN; INTENTION TO TREAT ANALYSIS; ISCHEMIC RISK; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SEX RATIO; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; THROMBOLYSIS IN MYOCARDIAL INFARCTION SCALE; TREND STUDY; UNITED STATES; VERY ELDERLY; YOUNG ADULT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FOLLOW UP; HEART INFARCTION; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS;

ADENOSINE MONOPHOSPHATE; ADULT; AGED; AGED, 80 AND OVER; CLOPIDOGREL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 85022164569     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.4556     Document Type: Article

References (44)

1. Winchester DE, Wen X, Brearley WD, Park KE, Anderson RD, Bavry AA. Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines. J Am Coll Cardiol. 2011;57(10): 1190-1199.
2. Sethi A, Bajaj A, Bahekar A, et al. Glycoprotein IIb/IIIa inhibitors with or without thienopyridine pretreatment improve outcomes after primary percutaneous coronary intervention in high-risk patients with ST elevation myocardial infarction-a meta-regression of randomized controlled trials. Catheter Cardiovasc Interv. 2013; 82(2):171-181.
3. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA. 2000;284(12):1549-1558.
4. Steg PG, van’t Hof A, Hamm CW, et al; EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013;369(23):2207-2217.
5. Stone GW, Witzenbichler B, Guagliumi G, et al; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218-2230.
6. Bhatt DL, Hulot JS, Moliterno DJ, Harrington RA. Antiplatelet and anticoagulation therapy for acute coronary syndromes. Circ Res. 2014;114(12): 1929-1943.
7. Hanna EB, Rao SV, Manoukian SV, Saucedo JF. The evolving role of glycoprotein IIb/IIIa inhibitors in the setting of percutaneous coronary intervention strategies to minimize bleeding risk and optimize outcomes. JACC Cardiovasc Interv. 2010;3(12):1209-1219.
8. Bhatt DL. Glycoprotein IIb/IIIa inhibitors: do they still have a role? J Am Coll Cardiol. 2011;57(10): 1200-1201.
9. Angiolillo DJ, Schneider DJ, Bhatt DL, et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) trials. J Thromb Thrombolysis. 2012; 34(1):44-55.
10. Ferreiro JL, Ueno M, Angiolillo DJ. Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther. 2009;7 (10):1195-1201.
11. Franchi F, Rollini F, Muñiz-Lozano A, Cho JR, Angiolillo DJ. Cangrelor: a review on pharmacology and clinical trial development. Expert Rev Cardiovasc Ther. 2013;11(10):1279-1291.
12. Keating GM. Cangrelor: a review in percutaneous coronary intervention. Drugs. 2015; 75(12):1425-1434.
13. Steg PG, Bhatt DL, Hamm CW, et al; CHAMPION Investigators. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013;382(9909):1981-1992.
14. Bhatt DL, Stone GW, Mahaffey KW, et al; CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14): 1303-1313.
15. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329(10):673-682.
16. Bhatt DL, Lincoff AM, Gibson CM, et al; CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361(24):2330-2341.
17. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361(24): 2318-2329.
18. Cutlip DE, Windecker S, Mehran R, et al; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17): 2344-2351.
19. Généreux P, Stone GW, Harrington RA, et al; CHAMPION PHOENIX Investigators. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol. 2014;63(7):619-629.
20. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction: design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am Heart J. 2005;149(2):217-226.
21. Stone GW, Bertrand M, Colombo A, et al. Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial: study design and rationale. Am Heart J. 2004;148(5):764-775.
22. Austin PC. A comparison of 12 algorithms for matching on the propensity score. Stat Med. 2014; 33(6):1057-1069.
23. Curzen N, Gurbel PA, Myat A, Bhatt DL, Redwood SR. What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention? Lancet. 2013;382(9892): 633-643.
24. Bhatt DL. Intensifying platelet inhibition-navigating between Scylla and Charybdis. N Engl J Med. 2007;357(20): 2078-2081.
25. Gutierrez A, Bhatt DL. Balancing the risks of stent thrombosis and major bleeding during primary percutaneous coronary intervention. Eur Heart J. 2014;35(36):2448-2451.
26. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation. 1995;92(9):2373-2380.
27. Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2016;67(10):1235-1250.
28. Safley DM, Venkitachalam L, Kennedy KF, Cohen DJ. Impact of glycoprotein IIb/IIIa inhibition in contemporary percutaneous coronary intervention for acute coronary syndromes: insights from the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2015;8(12): 1574-1582.
29. Dehmer GJ, Weaver D, Roe MT, et al. A contemporary view of diagnostic cardiac catheterization and percutaneous coronary intervention in the United States: a report from the CathPCI Registry of the National Cardiovascular Data Registry, 2010 through June 2011. J Am Coll Cardiol. 2012;60(20):2017-2031.
30. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8): 774-782.
31. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292(13):1555-1562.
32. Rao SV, Kaul PR, Liao L, et al. Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2008;155 (2):369-374.
33. Gurm HS, Hosman C, Bates ER, Share D, Hansen BB; Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Comparative effectiveness and safety of a catheterization laboratory-only eptifibatide dosing strategy in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 2015;8(2): e001880.
34. O’Donoghue M, Antman EM, Braunwald E, et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38) analysis. J Am Coll Cardiol. 2009;54(8): 678-685.
35. Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057.
36. Fan W, Plent S, Prats J, Deliargyris EN. Trends in P2Y12 inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice. Am J Cardiol. 2016;117 (9):1439-1443.
37. Schneider DJ, Seecheran N, Raza SS, Keating FK, Gogo P. Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron Artery Dis. 2015;26(1):42-48.
38. Schneider DJ, Agarwal Z, Seecheran N, Keating FK, Gogo P. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv. 2014;7(4):435-442.
39. Heestermans AA, van Werkum JW, Taubert D, et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res. 2008;122(6):776-781.
40. Součková L, Opatřilová R, Suk P, et al. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). Eur J Clin Pharmacol. 2013;69 (3):309-317.
41. Alexopoulos D, Bhatt DL, Hamm CW, Steg PG, Stone GW. Early P2Y12 inhibition in ST-segment elevation myocardial infarction: bridging the gap. Am Heart J. 2015;170(1):3-12.
42. White HD, Bhatt DL, Gibson CM, et al. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (a Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). JACC Cardiovasc Interv. 2015;8 (3):424-433.
43. Vaduganathan M, Harrington RA, Stone GW, et al. Variation in patient profiles and outcomes in US and non-US subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. Circ Cardiovasc Interv. 2016;9(6):e003612.
44. Jatene T, Harrington RA, Stone GW, et al; CHAMPION PHOENIX Investigators. Investigator-reported bleeding versus post hoc adjudication of bleeding: lessons from the CHAMPION PHOENIX trial. J Am Coll Cardiol. 2016; 67(5):596-598.